Nephrocare Health Services Credit Rating
India Ratings upgraded Nephrocare Health Services' long-term bank loan facilities to IND AA-/Stable. The agency also affirmed the company's short-term credit ratings.
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
11 announcements
India Ratings upgraded Nephrocare Health Services' long-term bank loan facilities to IND AA-/Stable. The agency also affirmed the company's short-term credit ratings.
Nephrocare Health Services Ltd announced the rationalisation and consolidation of its step-down subsidiaries in the Philippines. This internal reorganization streamlines the group's existing structure.
Nephrocare's Philippines subsidiary acquired a dialysis center from Renal One Dialysis Corp for ≈₹10.25 Cr. The asset transfer expands the company's dialysis network.
Nephrocare's Philippines subsidiary is acquiring a dialysis center from Renal One Dialysis Corp. for a consideration of ₹10.25 crore.
Nephrocare Health Services granted 4,01,362 employee stock options at an exercise price of ₹230 per share. These options are issued under the NephroPlus Employee Stock Option Scheme 2026.
Nephrocare delivered robust 23.7% revenue growth driven by international expansion and volume gains. While margins improved via operating leverage, high working capital cycles and binary outcomes in tender markets like Saudi Arabia remain key risks.
Nephrocare Health Services (NephroPlus) reported Q1FY27 revenue of ₹281.8 Cr, up 23.7% YoY. Strategy focuses on international scaling and high-margin organized dialysis network leadership.
Nephrocare Health Services Ltd reported revenue from operations of ₹281.8 Cr (+23.7% YoY) and net profit of ₹32 Cr (+35.0% YoY) for Q1 FY27.
Nephrocare reports strong FY26 performance with 32% revenue growth and significant margin expansion, driven by international expansion and platform-led operational efficiencies.
Nephrocare Health Services (NephroPlus) reported strong FY26 performance with revenue reaching ₹998.8 Cr, driven by international expansion and increased treatment volumes.
Nephrocare Health Services Ltd reported revenue from operations of ₹265.6 Cr (+21.2% YoY) and net profit of ₹30.4 Cr (+22.1% YoY) for Q4 FY26.